Russia's AIMP lodges another plea on drug labeling

20 July 2020

The Russian Association of International Pharmaceutical Manufacturers (AIPM) is asking for changes to the rules for the introduction of unlabeled drugs into civil circulation.

It proposes removal of the clause that, in order to obtain the consent of the interagency commission it is necessary to attach copies of contracts for the supply and installation of equipment for applying codes, as well as for software development. This information cannot be provided without permission from counterparties, the trade group points out.

The AIPM proposes amendments to subparagraph c) of paragraph 7 of the Decree of the Government of the Russian Federation on the provisional procedure for the introduction of unlabeled drugs into civilian traffic. Instead of copies of contracts for the supply and installation of equipment for applying codes, as well as for the development of software, it is advisable to limit ourselves to simple confirmation of the existence of such contracts. This is stated in a letter from the AIPM dated July 15, sent to the Deputy Prime Minister of Russia, Tatyana Golikova.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK